Anticoagulant, Antithrombotic and Anti-Platelet Drugs www.freelivedoctor.com
Clinical Thrombosis <ul><li>>2.5 million cases of deep venous thrombosis (DVT) per year </li></ul><ul><li>>600,000 cases o...
Indications For Antithrombotic Therapy <ul><li>Venous thromboembolic disease </li></ul><ul><ul><li>Deep venous thrombosis ...
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
Recombinant Human Activated Protein C <ul><li>Drotrecogin alfa (activated)- Xigris </li></ul><ul><li>Indicated for Severe ...
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
Antithrombin III Inhibits the Following Serine Proteases <ul><li>Coagulation </li></ul><ul><li>Factor XIIa </li></ul><ul><...
Heparin <ul><li>Heterogeneous; 3,000-30,000 d  </li></ul><ul><li>Average=15,000 d (~45monosaccharide chains) </li></ul><ul...
www.freelivedoctor.com
Anticoagulant Properties of Heparin <ul><li>Inhibits the thrombin-mediated conversion of fibrinogen to fibrin </li></ul><u...
Heparin <ul><li>Biologic Sources </li></ul><ul><li>Bioavailability </li></ul><ul><li>Metabolism </li></ul><ul><li>Eliminat...
www.freelivedoctor.com
Unfractionated Heparin <ul><li>High Dose </li></ul><ul><ul><li>Treatment of venous/arterial thrombi </li></ul></ul><ul><ul...
www.freelivedoctor.com
Monitoring of Anticoagulant Therapy <ul><li>Heparin </li></ul><ul><li>s.q. – no monitoring required </li></ul><ul><li>i.v....
www.freelivedoctor.com
Low Dose Unfractionated Heparin <ul><li>Surgical  Prophylaxis </li></ul><ul><ul><li>5,000 Units SQ 2 hr preop </li></ul></...
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
Indications for and Contraindications to  Parenteral Anticoagulant Agents www.freelivedoctor.com Anticoagulant Agent Class...
Indications for and Contraindications to  Parenteral Anticoagulant Agents (cont’d) www.freelivedoctor.com Ardeparin Lepiru...
www.freelivedoctor.com
Heparin-Antibiotic Interactions <ul><li>The second-generation cephalosporins- cefamandole, cefotetan, and cefoperazone, co...
www.freelivedoctor.com
Mechanisms of HIT <ul><li>Type 1: In most of these cases, the fall in platelet count occurs within the first two days afte...
www.freelivedoctor.com
Therapy of HIT <ul><li>There are two recommended approaches:  </li></ul><ul><ul><li>Use of the heparinoid danaparoid  </li...
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
Warfarin <ul><li>Bioavailability </li></ul><ul><li>Metabolism </li></ul><ul><li>Serum Protein Binding </li></ul><ul><li>Vi...
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
www.freelivedoctor.com
Contraindications to Antithrombotic Therapy <ul><li>General risk factors </li></ul><ul><li>-Pre-existing coagulation or pl...
Contraindications to  Antithrombotic Therapy <ul><li>Specific to warfarin (ambulatory patients) </li></ul><ul><li>-Early a...
Contraindications to Antithrombotic Therapy <ul><li>Specific to thrombolytic agents </li></ul><ul><li>-Recent thoracic, ab...
Platelet Receptor Mediated Pathways: Drugs www.freelivedoctor.com Arachidonic Acid ASA NSAIDs ADP Ticlopidine Clopidogrel ...
Anti Platelet Drugs www.freelivedoctor.com Drug Mechanism Uses Aspirin Permanently inhibits COX-1 and COX-2 CAD Stroke-TIA...
Upcoming SlideShare
Loading in...5
×

Anticoagulant, antithrombotic and anti platelet drugs

21,678
-1

Published on

1 Comment
26 Likes
Statistics
Notes
No Downloads
Views
Total Views
21,678
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1,454
Comments
1
Likes
26
Embeds 0
No embeds

No notes for slide

Anticoagulant, antithrombotic and anti platelet drugs

  1. 1. Anticoagulant, Antithrombotic and Anti-Platelet Drugs www.freelivedoctor.com
  2. 2. Clinical Thrombosis <ul><li>>2.5 million cases of deep venous thrombosis (DVT) per year </li></ul><ul><li>>600,000 cases of pulmonary embolism (PE) per year </li></ul><ul><li>>50,000 deaths per year from PE </li></ul><ul><li>PE contributes to another 150,000 deaths per year </li></ul><ul><li>> 11,000 postsurgical PE deaths per year </li></ul>www.freelivedoctor.com
  3. 3. Indications For Antithrombotic Therapy <ul><li>Venous thromboembolic disease </li></ul><ul><ul><li>Deep venous thrombosis (DVT) </li></ul></ul><ul><ul><li>Pulmonary embolism (PE) </li></ul></ul><ul><ul><li>Primary prophylaxis of DVT or PE </li></ul></ul><ul><li>Arterial thromboembolic disease </li></ul><ul><ul><li>Prosthetic heart valves </li></ul></ul><ul><ul><li>Mitral valve disease, especially with atrial fibrillation </li></ul></ul><ul><ul><li>Congestive cardiomyopathies, especially with atrial fibrillatio </li></ul></ul><ul><ul><li>Atrial fibrillation </li></ul></ul><ul><ul><li>Mural cardiac thrombi </li></ul></ul><ul><ul><li>Transient ischemic attacks </li></ul></ul><ul><ul><li>Stroke in evolution </li></ul></ul><ul><li>Disseminated intravascular coagulation </li></ul><ul><li>Maintenance of patency of vascular grafts, shunts, bypasses </li></ul>www.freelivedoctor.com
  4. 4. www.freelivedoctor.com
  5. 5. www.freelivedoctor.com
  6. 6. www.freelivedoctor.com
  7. 7. www.freelivedoctor.com
  8. 8. www.freelivedoctor.com
  9. 9. www.freelivedoctor.com
  10. 10. www.freelivedoctor.com
  11. 11. Recombinant Human Activated Protein C <ul><li>Drotrecogin alfa (activated)- Xigris </li></ul><ul><li>Indicated for Severe Sepsis in Adults with Acute Organ Dysfunction with High Risk of Death </li></ul><ul><li>Reduction in Death as Primary End Point </li></ul><ul><li>Antithrombotic, Antiinfammatory, Profibrinolytic Properties </li></ul><ul><li>Serious Bleeding is Major Side Effect </li></ul>www.freelivedoctor.com
  12. 12. www.freelivedoctor.com
  13. 13. www.freelivedoctor.com
  14. 14. www.freelivedoctor.com
  15. 15. www.freelivedoctor.com
  16. 16. www.freelivedoctor.com
  17. 17. www.freelivedoctor.com
  18. 18. www.freelivedoctor.com
  19. 19. www.freelivedoctor.com
  20. 20. Antithrombin III Inhibits the Following Serine Proteases <ul><li>Coagulation </li></ul><ul><li>Factor XIIa </li></ul><ul><li>Factor XIa </li></ul><ul><li>Factor IXa </li></ul><ul><li>Factor Xa </li></ul><ul><li>Thrombin </li></ul><ul><li>Fibrinolysis </li></ul><ul><li>Plasmin </li></ul>Inhibitory activity against all these enzymes is substantially accelerated by heparin www.freelivedoctor.com
  21. 21. Heparin <ul><li>Heterogeneous; 3,000-30,000 d </li></ul><ul><li>Average=15,000 d (~45monosaccharide chains) </li></ul><ul><li>About 1/3 of dose binds to AT III </li></ul><ul><li>To form the AT III:Heparin:Clotting Factor Complex- requires at least 18 saccarides except </li></ul><ul><li>Unique high affinity pentasaccaride heparin sequences catalyze inhibition of Xa by AT </li></ul>www.freelivedoctor.com
  22. 22. www.freelivedoctor.com
  23. 23. Anticoagulant Properties of Heparin <ul><li>Inhibits the thrombin-mediated conversion of fibrinogen to fibrin </li></ul><ul><li>Inhibits the aggregation of platelets by thrombin </li></ul><ul><li>Inhibits activation of fibrin stabilizing enzyme </li></ul><ul><li>Inhibits activated factors XII, XI, IX, X and II </li></ul>www.freelivedoctor.com
  24. 24. Heparin <ul><li>Biologic Sources </li></ul><ul><li>Bioavailability </li></ul><ul><li>Metabolism </li></ul><ul><li>Elimination </li></ul><ul><li>Side Effects </li></ul><ul><li>Overdose </li></ul><ul><li>Contraindications </li></ul><ul><li>Pregnancy- YES </li></ul>www.freelivedoctor.com
  25. 25. www.freelivedoctor.com
  26. 26. Unfractionated Heparin <ul><li>High Dose </li></ul><ul><ul><li>Treatment of venous/arterial thrombi </li></ul></ul><ul><ul><li>Requires monitoring </li></ul></ul><ul><ul><li>IV- 5,000 Units bolus, then 30,000-35,000 units/24 hrs </li></ul></ul><ul><ul><li>80 Units/kg bolus, then 18 Units/kg/hr to maintain aPTT in therapeutic range </li></ul></ul>www.freelivedoctor.com
  27. 27. www.freelivedoctor.com
  28. 28. Monitoring of Anticoagulant Therapy <ul><li>Heparin </li></ul><ul><li>s.q. – no monitoring required </li></ul><ul><li>i.v. - partial thromboplastin time (P.T.T.) </li></ul><ul><li>*daily or more frequent if PTT varies </li></ul><ul><li>mechanism – measures intrinsic pathway </li></ul><ul><li>therapeutic goal – 2-2.5 times normal control value (-30 sec) </li></ul>www.freelivedoctor.com
  29. 29. www.freelivedoctor.com
  30. 30. Low Dose Unfractionated Heparin <ul><li>Surgical Prophylaxis </li></ul><ul><ul><li>5,000 Units SQ 2 hr preop </li></ul></ul><ul><ul><li>5,000 Units SQ every 12 hours </li></ul></ul><ul><li>Medical Prophylaxis </li></ul><ul><ul><li>5,000 Units SQ every 12 hours </li></ul></ul><ul><li>No monitoring required </li></ul>www.freelivedoctor.com
  31. 31. www.freelivedoctor.com
  32. 32. www.freelivedoctor.com
  33. 33. www.freelivedoctor.com
  34. 34. Indications for and Contraindications to Parenteral Anticoagulant Agents www.freelivedoctor.com Anticoagulant Agent Class Approved & Appropriate Indications Contraindication Unfractionated heparin Enoxaparin ( Lovenox ) Dalteparin ( Fragmin ) Tinzaparin ( Innohep ) Antithrombin III inhibitor Low-molecular-weight heparin Low-molecular-weight heparin Low-molecular-weight heparin Treatment of venous thromboembolism or unstable angina; used when rapid reversal is important Prophylaxis in moderate-risk or high-risk patients, treatment of venous thromboembolism or unstable angina Prophylaxis in moderate-risk or high-risk patients, treatment of venous thromboembolism or unstable angina Prophylaxis in moderate-risk or high-risk patients, treatment of venous thromboembolism ? Prophylactic treatment Regional anesthesia Pregnancy Prosthetic Heart Valves Regional anesthesia Regional anesthesia
  35. 35. Indications for and Contraindications to Parenteral Anticoagulant Agents (cont’d) www.freelivedoctor.com Ardeparin Lepirudin Argatroban Danaparoid Bivalirudin Fondaparinux ( Arixtra ) Low-molecular-weight heparin Hirudin derivative Direct thrombin inhibitor Heparinoid Hirudin derivative Synthetic factor Xa inhibitor Approved; not being marketed Heparin-induced thrombocytopenia with thrombosis Heparin-induced thrombocytopenia with thrombosis Prophylaxis against thrombosis in heparin-induced thrombocytopenia Unstable angina or angioplasty Prophylaxis in high-risk patients? Regional anesthesia Thrombocytopenia other than heparin-induced thrombocytopenia Thrombocytopenia other than heparin-induced thrombocytopenia Thrombocytopenia other than heparin-induced thrombocytopenia Unknown Unknown
  36. 36. www.freelivedoctor.com
  37. 37. Heparin-Antibiotic Interactions <ul><li>The second-generation cephalosporins- cefamandole, cefotetan, and cefoperazone, contain an N-methylthiotetrazole (NMTT) side chain. This NMTT group can: </li></ul><ul><li>- Dissociate from the parent antibiotic in solution or in vivo and competitively inhibit vitamin K action, leading to prolongation of the prothrombin time and bleeding. </li></ul><ul><li>- This side chain is also associated with a disulfiram-like reaction to alcohol. </li></ul><ul><li>- Clinical bleeding has been less frequently reported with Cefotetan than with cefoperazone or cefamandole. </li></ul>www.freelivedoctor.com
  38. 38. www.freelivedoctor.com
  39. 39. Mechanisms of HIT <ul><li>Type 1: In most of these cases, the fall in platelet count occurs within the first two days after heparin initiation, often returns to normal with continued heparin administration, and is of no clinical consequence. The mechanism of the thrombocytopenia is non-immune and appears to be due to a direct effect of heparin on platelet activation. </li></ul><ul><li>    Type 2: Approximately 0.3 to 3 percent of patients receiving heparin develop an immune thrombocytopenia, mediated by antibodies to a heparin-platelet factor 4 complex. One study, for example, randomly assigned 665 patients to therapy with unfractionated heparin or LMW heparin. Type 2 HIT developed in 2.7 percent of patients treated with unfractionated heparin but in none of those receiving LMW heparin. </li></ul>www.freelivedoctor.com
  40. 40. www.freelivedoctor.com
  41. 41. Therapy of HIT <ul><li>There are two recommended approaches: </li></ul><ul><ul><li>Use of the heparinoid danaparoid </li></ul></ul><ul><ul><li>The direct thrombin inhibitor lepirudin (recombinant hirudin) </li></ul></ul><ul><ul><li>Based upon the data published to date, either danaparoid or lepirudin should be used to treat HIT that is complicated by thrombosis; these agents should also be considered for prophylactic therapy in patients with HIT without thrombosis until the platelet count has recovered </li></ul></ul>www.freelivedoctor.com
  42. 42. www.freelivedoctor.com
  43. 43. www.freelivedoctor.com
  44. 44. www.freelivedoctor.com
  45. 45. www.freelivedoctor.com
  46. 46. www.freelivedoctor.com
  47. 47. www.freelivedoctor.com
  48. 48. www.freelivedoctor.com
  49. 49. Warfarin <ul><li>Bioavailability </li></ul><ul><li>Metabolism </li></ul><ul><li>Serum Protein Binding </li></ul><ul><li>Vitamin K Status </li></ul><ul><li>Protein C Effects </li></ul><ul><li>Elimination </li></ul><ul><li>Side Effects </li></ul><ul><li>Overdose </li></ul><ul><li>Contraindications </li></ul><ul><li>Pregnancy- NO </li></ul>www.freelivedoctor.com
  50. 50. www.freelivedoctor.com
  51. 51. www.freelivedoctor.com
  52. 52. www.freelivedoctor.com
  53. 53. www.freelivedoctor.com
  54. 54. www.freelivedoctor.com
  55. 55. www.freelivedoctor.com
  56. 56. www.freelivedoctor.com
  57. 57. www.freelivedoctor.com
  58. 58. www.freelivedoctor.com
  59. 59. Contraindications to Antithrombotic Therapy <ul><li>General risk factors </li></ul><ul><li>-Pre-existing coagulation or platelet defect, thrombocytopenia, or other bleeding abnormality </li></ul><ul><li>-Inaccessible ulcerative lesion (e.g., gastrointestinal tract lesion) </li></ul><ul><li>-Central nervous system lesion (e.g., caused by stroke, surgery, trauma) </li></ul><ul><li>-Spinal anesthesia or lumbar puncture </li></ul><ul><li>-Malignant hypertension </li></ul><ul><li>-Bacterial endocarditis </li></ul><ul><li>-Advanced retinopathy </li></ul><ul><li>-Old age (relative) </li></ul><ul><li>-Aspirin or other antiplatelet drugs </li></ul><ul><li>-Neoplastic disease </li></ul>www.freelivedoctor.com
  60. 60. Contraindications to Antithrombotic Therapy <ul><li>Specific to warfarin (ambulatory patients) </li></ul><ul><li>-Early and late pregnancy </li></ul><ul><li>-Poor patient cooperation, understanding, reliability </li></ul><ul><li>-Unsatisfactory laboratory or patient follow-up </li></ul><ul><li>-Occupational risk to trauma </li></ul>www.freelivedoctor.com
  61. 61. Contraindications to Antithrombotic Therapy <ul><li>Specific to thrombolytic agents </li></ul><ul><li>-Recent thoracic, abdominal, or central nervous system surgery </li></ul><ul><li>-Recent cerebrovascular accident, trauma, or neoplasm </li></ul><ul><li>-Bleeding ulcer </li></ul><ul><li>-Hypertension </li></ul><ul><li>-Anticipated invasive procedures (arterial punctures, biopsies, central lines) </li></ul><ul><li>-Concurrent hemostatic dysfunction </li></ul>www.freelivedoctor.com
  62. 62. Platelet Receptor Mediated Pathways: Drugs www.freelivedoctor.com Arachidonic Acid ASA NSAIDs ADP Ticlopidine Clopidogrel Thrombin -Final Common Pathway -Promotes Platelet Adhesion (Fibrinogen, vWF) GP IIB/IIIA Inhibitors Abciximab (ReoPro) Eptifibatide (Integrilin) Tirofiban
  63. 63. Anti Platelet Drugs www.freelivedoctor.com Drug Mechanism Uses Aspirin Permanently inhibits COX-1 and COX-2 CAD Stroke-TIAs NSAIDs Reversibly inhibits COX-1 Limited Dipyridamole Inhibits PDE; increases cAMP TIAs Ticlopidine Clopidrgrel Inhibits ADP PlatAg;active metabolite TIAs;Stroke CAD;PVD
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×